Stockreport

Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer

GENEREX BIOTECHNOLOGY  (GNBT) 
US:NASDAQ Investor Relations: generex.com/investor
PDF MIRAMAR, Fla.--(BUSINESS WIRE)-- Generex Biotechnology Corporation (OTCQB:GNBT) today announced that the FDA had reviewed the company’s investigational new [Read more]